Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial
帕博利珠单抗联合化疗治疗晚期或复发性子宫内膜癌:NRG GY018 3期随机试验的总生存期和探索性分析
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03566-1
Eskander, Ramez N; Sill, Michael W; Beffa, Lindsey; Moore, Richard G; Hope, Joanie M; Musa, Fernanda B; Mannel, Robert S; Shahin, Mark S; Cantuaria, Guilherme H; Girda, Eugenia; Lokich, Elizabeth; Kavecansky, Juraj; Leath, Charles A 3rd; Gien, Lilian T; Hinchcliff, Emily M; Lele, Shashikant B; Landrum, Lisa M; Backes, Floor; O'Cearbhaill, Roisin E; Baghdadi, Tareq Al; Hill, Emily K; Thaker, Premal H; John, Veena S; Welch, Stephen; Fader, Amanda N; Powell, Matthew A; Aghajanian, Carol